AUM: $3.4B · Form ADV, 30 Mar 2026
| i | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nasdaq: ZYME | Current | Pharmaceutical Preparations | COM | 22,970,388 | 0 | 0.0% | 33.28% | $608M | +$8M | 27.01% | $1.9B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ANAB | Current | Pharmaceutical Preparations | COM | 7,880,094 | 0 | 0.0% | 26.36% | $396M | -$136M | 17.58% | $1.4B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: BMY | Current | Pharmaceutical Preparations | COM | New | $218M | +$218M | 9.70% | $119B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | ||||
| Nasdaq: CGON | Current | Biological Products, (No Diagnostic Substances) | COM | 1,871,892 | +377,592 | +25.3% | 2.10% | $133M | -$13M | 5.89% | $7.3B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Eton Pharmaceuticals, Inc. | Nasdaq: ETON | Current | Pharmaceutical Preparations | COM | 2,470,920 | +298,982 | +13.8% | 8.57% | $127M | +$49M | 5.65% | $1.8B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| First Tracks Biotherapeutics, Inc. | Nasdaq: TRAX | Current | Pharmaceutical Preparations | ORD SHS | 3,174,519 | 0 | 0.0% | 7.56% | $113M | +$49M | 4.99% | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: AKTS | Current | Pharmaceutical Preparations | COM | 4,824,469 | 0 | 0.0% | $94M | -$62M | 4.17% | $915M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: CRSP | Current | Biological Products, (No Diagnostic Substances) | NAMEN AKT | 1,389,276 | 0 | 0.0% | 1.43% | $77M | +$1M | 3.41% | $3.8B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: ANRO | Current | Pharmaceutical Preparations | SHSCOM | 2,232,000 | +2,232,000 | New | 5.56% | $57M | +$57M | 2.53% | $1.1B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: LKFT | Current | Pharmaceutical Preparations | SPON ADR | 1,667,119 | 0 | 0.0% | $49M | -$0.6M | 2.19% | $2.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: ERAS | Current | Pharmaceutical Preparations | COM | 2,950,000 | +2,620,000 | +793.9% | 0.84% | $43M | +$37M | 1.92% | $5.0B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ORIC | Current | Pharmaceutical Preparations | COM | 3,028,116 | -3,700,000 | -55.0% | 2.91% | $41M | -$32M | 1.81% | $800M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Neurogene Inc. | Nasdaq: NGNE | Current | Pharmaceutical Preparations | COM | 1,271,342 | 0 | 0.0% | 6.14% | $35M | -$5M | 1.57% | $475M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Attovia Therapeutics, Inc. | Nasdaq: ATTO | Current | Biological Products, (No Diagnostic Substances) | COM ADDED | 2,024,010 | +2,024,010 | New | 4.43% | $35M | +$35M | 1.54% | $712M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: FULC | Current | Pharmaceutical Preparations | COM | 6,803,785 | +253,919 | +3.9% | 8.91% | $25M | +$1M | 1.12% | $283M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ADRX | Current | Pharmaceutical Preparations | COM ADDED | 1,150,000 | +1,150,000 | New | 1.03% | $23M | +$23M | 1.02% | $1.6B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: STOK | Current | Pharmaceutical Preparations | COM | 835,000 | +100,000 | +13.6% | 1.28% | $22M | -$2M | 0.96% | $1.8B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ZBIO | Current | Pharmaceutical Preparations | COM | 789,500 | 0 | 0.0% | 1.16% | $21M | +$1M | 0.95% | $1.7B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ETRA | Current | Biological Products, (No Diagnostic Substances) | COM ADDED | 1,700,000 | +1,700,000 | New | 2.70% | $19M | +$19M | 0.85% | $561M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ATRA | Current | Biological Products, (No Diagnostic Substances) | COM NEW | 1,552,000 | 0 | 0.0% | 15.23% | $13M | -$5M | 0.59% | $65M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CAPR | Current | Pharmaceutical Preparations | COM NEW | 1,376,580 | +1,376,580 | New | 2.37% | $13M | +$13M | 0.58% | $438M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: XNCR | Current | Pharmaceutical Preparations | COM | 500,000 | +500,000 | New | 0.67% | $12M | +$12M | 0.55% | $2.6B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Odyssey Therapeutics, Inc. | Nasdaq: ODTX | Current | Biological Products, (No Diagnostic Substances) | COMMON STOCK | 555,555 | 0 | 0.0% | 1.16% | $12M | +$2M | 0.55% | $882M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Aura Biosciences, Inc. | Nasdaq: AURA | Current | Biological Products, (No Diagnostic Substances) | COM | 1,666,667 | 0 | 0.0% | 1.60% | $10M | -$1M | 0.46% | $726M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: NRIX | Current | Pharmaceutical Preparations | COM | 375,000 | +105,000 | +38.9% | 0.34% | $9M | +$2M | 0.39% | $1.5B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| Braveheart Bio, Inc. | Nasdaq: BRVE | Current | Pharmaceutical Preparations | SHSCOM ADDED | 416,700 | +416,700 | New | 0.46% | $8M | +$8M | 0.37% | $1.6B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: PHVS | Current | Pharmaceutical Preparations | COM | 235,000 | 0 | 0.0% | $7M | -$0.7M | 0.33% | $2.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Eikon Therapeutics, Inc. | Nasdaq: EIKN | Current | Biological Products, (No Diagnostic Substances) | COM | 855,634 | +123,028 | +16.8% | 1.58% | $7M | -$3M | 0.31% | $258M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 |
| Eloxx Pharmaceuticals, Inc. | Nasdaq: ELOX | Current | Biological Products, (No Diagnostic Substances) | COM NEW | 400,000 | 0 | 0.0% | 9.79% | $6M | +$0.6M | 0.27% | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| Aardvark Therapeutics, Inc. | Nasdaq: AARD | Current | Pharmaceutical Preparations | COM | 720,028 | +323,834 | +81.7% | 3.29% | $4M | +$1M | 0.17% | $22M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: BBOT | Current | Pharmaceutical Preparations | COM NEW | 889,607 | -1,933,519 | -68.5% | 1.11% | $4M | -$18M | 0.16% | $149M | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | |
| TCGX Acquisition Corp. | Nasdaq: TCGX | Current | Blank Checks | CL AORD ADDED | 250,000 | +250,000 | New | $3M | +$3M | 0.14% | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Zura Bio Ltd | Nasdaq: ZURA | Current | Biological Products, (No Diagnostic Substances) | CLASS A ORD SHS | 679,715 | -500,000 | -42.4% | 0.71% | $3M | -$4M | 0.13% | $92M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 |
| Helix Acquisition Corp. III | Nasdaq: HLXC | Current | Blank Checks | CL A ORD SHS | 200,000 | 0 | 0.0% | $2M | -$0.0M | 0.09% | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: CTNM | Current | Pharmaceutical Preparations | CL A | 64,303 | +64,303 | New | $0.9M | +$0.9M | 0.04% | $355M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: JAZZ | Exited | Pharmaceutical Preparations | SHS USD | 0 | -1,706,469 | -100.0% | -$323M | $15.2B | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||
| Centessa Pharmaceuticals PLC | Exited | SPONSORED ADS | 0 | -6,000,000 | -100.0% | -$255M | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||||
| Uniqure NV | Exited | SHS | 0 | -3,988,971 | -100.0% | -$233M | Q4 2025 | 17 Feb 2026 | Q4 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| Crinetics Pharmaceuticals Inc | Exited | COM | 0 | -4,288,120 | -100.0% | -$156M | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||||
| Prothena Corp PLC | Exited | SHS | 0 | -11,584,280 | -100.0% | -$143M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| NYSE: PFE | Exited | Pharmaceutical Preparations | COM | -100.0% | -$133M | $156B | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Nasdaq: ARVN | Exited | Pharmaceutical Preparations | COM | 0 | -6,726,491 | -100.0% | -$129M | $441M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Iteos Therapeutics Inc | Exited | COM | 0 | -10,688,978 | -100.0% | -$107M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||||
| Nasdaq: TNGX | Exited | Pharmaceutical Preparations | COM | 0 | -10,630,736 | -100.0% | -$89M | $3.8B | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: SRPT | Exited | Pharmaceutical Preparations | COM | 0 | -1,292,386 | -100.0% | -$82M | $1.5B | Q2 2025 | 14 Aug 2025 | Q4 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Apellis Pharmaceuticals Inc | Exited | COM | 0 | -3,447,156 | -100.0% | -$78M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| Nasdaq: IMNM | Exited | Pharmaceutical Preparations | COM | 0 | -2,855,590 | -100.0% | -$61M | $2.0B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Springworks Therapeutics Inc | Exited | COM | 0 | -1,560,000 | -100.0% | -$56M | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Viridian Therapeutics, Inc.\DE | Nasdaq: VRDN | Exited | Pharmaceutical Preparations | COM | 0 | -1,958,847 | -100.0% | -$45M | $3.6B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | |||
| Nasdaq: MDGL | Exited | Pharmaceutical Preparations | COM | 0 | -75,000 | -100.0% | -$34M | $9.2B | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: JANX | Exited | Pharmaceutical Preparations | COM | 0 | -1,469,818 | -100.0% | -$34M | $630M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| Nasdaq: EWTX | Exited | Pharmaceutical Preparations | COM | 0 | -1,250,385 | -100.0% | -$33M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | |||||
| Avidity Biosciences Inc | Exited | COM | 0 | -765,000 | -100.0% | -$33M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| Third Harmonic Bio Inc | Exited | COM | 0 | -3,182,444 | -100.0% | -$33M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Akero Therapeutics Inc | Exited | COM | 0 | -440,000 | -100.0% | -$23M | Q3 2025 | 14 Nov 2025 | Q1 2025 | Q2 2025 | 13F, Q2 2025 | ||||||
| Nasdaq: GPCR | Exited | Pharmaceutical Preparations | SPONSORED ADS | 0 | -334,380 | -100.0% | -$23M | $1.2B | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: LEGN | Exited | Pharmaceutical Preparations | SPONSORED ADS | 0 | -800,000 | -100.0% | -$23M | $3.1B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: CLDX | Exited | In Vitro & In Vivo Diagnostic Substances | COM NEW | 0 | -650,000 | -100.0% | -$22M | $2.2B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Nasdaq: NMRA | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -2,071,450 | -100.0% | -$22M | $65M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| MBX Biosciences, Inc. | Nasdaq: MBX | Exited | Pharmaceutical Preparations | COM | 0 | -388,500 | -100.0% | -$21M | $2.7B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | |||
| Cargo Therapeutics Inc | Exited | COM | 0 | -1,470,000 | -100.0% | -$21M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Nasdaq: PCVX | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -450,000 | -100.0% | -$21M | $9.2B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: IONS | Exited | Pharmaceutical Preparations | COM | 0 | -500,000 | -100.0% | -$20M | $4.5B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Verona Pharma PLC | Exited | SPONSORED ADS | 0 | -200,000 | -100.0% | -$19M | Q3 2025 | 14 Nov 2025 | Q2 2025 | Q2 2025 | 13F, Q2 2025 | ||||||
| Tectonic Therapeutic, Inc. | Nasdaq: TECX | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -935,121 | -100.0% | -$19M | $411M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | |||
| Nasdaq: MLTX | Exited | Pharmaceutical Preparations | CLASS A ORD | 0 | -332,522 | -100.0% | -$18M | $939M | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: AQST | Exited | Pharmaceutical Preparations | COM | 0 | -2,625,000 | -100.0% | -$17M | $466M | Q1 2026 | 15 May 2026 | Q3 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Mersana Therapeutics Inc | Exited | COM | 0 | -11,328,000 | -100.0% | -$16M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Nasdaq: VYGR | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -4,002,847 | -100.0% | -$16M | $100M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: ALKS | Exited | Pharmaceutical Preparations | SHS | 0 | -500,000 | -100.0% | -$15M | $7.8B | Q4 2025 | 17 Feb 2026 | Q2 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| Metsera Inc | Exited | COM | 0 | -271,529 | -100.0% | -$14M | Q4 2025 | 17 Feb 2026 | Q1 2025 | Q3 2025 | 13F, Q3 2025 | ||||||
| Nasdaq: KYMR | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -350,000 | -100.0% | -$14M | $10.2B | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: DYN | Exited | Pharmaceutical Preparations | COM | 0 | -555,644 | -100.0% | -$13M | $3.0B | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: RLAY | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -697,948 | -100.0% | -$13M | $3.5B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | ||||
| Atea Pharmaceuticals, Inc. | Nasdaq: AVIR | Exited | Pharmaceutical Preparations | COM | 0 | -3,341,653 | -100.0% | -$11M | $316M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | |||
| Pacira BioSciences, Inc. | Nasdaq: PCRX | Exited | Pharmaceutical Preparations | COM | 0 | -457,471 | -100.0% | -$11M | $1.5B | Q3 2025 | 14 Nov 2025 | Q2 2025 | Q2 2025 | 13F, Q2 2025 | |||
| Nasdaq: BEAM | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -526,685 | -100.0% | -$10M | $2.2B | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | ||||
| Nasdaq: MNKD | Exited | Pharmaceutical Preparations | COM NEW | 0 | -1,660,000 | -100.0% | -$9M | $1.3B | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| NYSE: NUVB | Exited | Pharmaceutical Preparations | *W EXP 02/10/202 | 0 | -963,333 | -100.0% | -$9M | $1.3B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: PRME | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -1,543,326 | -100.0% | -$9M | $856M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| NYSE: DNA | Exited | Biological Products, (No Diagnostic Substances) | CL A NEW | 0 | -1,462,328 | -100.0% | -$8M | $532M | Q2 2025 | 14 Aug 2025 | Q4 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Nasdaq: LENZ | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -346,772 | -100.0% | -$8M | $105M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Nasdaq: BCYC | Exited | Pharmaceutical Preparations | SPONSORED ADS | 0 | -910,000 | -100.0% | -$8M | $214M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Nasdaq: KURA | Exited | Pharmaceutical Preparations | COM | 0 | -872,500 | -100.0% | -$8M | $675M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: REPL | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -1,000,000 | -100.0% | -$8M | $1.8B | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: PHAT | Exited | Pharmaceutical Preparations | COM | 0 | -625,000 | -100.0% | -$7M | $413M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| OTC: ADAPY | Exited | Biological Products, (No Diagnostic Substances) | SPONDS ADS | 0 | -27,404,070 | -100.0% | -$7M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | |||||
| Verve Therapeutics Inc | Exited | COM | 0 | -1,250,000 | -100.0% | -$6M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| Day One Biopharmaceuticals Inc | Exited | COM | 0 | -862,068 | -100.0% | -$6M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||||
| Nasdaq: FATE | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -3,049,405 | -100.0% | -$5M | $123M | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Hillevax Inc | Exited | COM | 0 | -2,420,243 | -100.0% | -$5M | Q3 2025 | 14 Nov 2025 | Q2 2025 | Q2 2025 | 13F, Q2 2025 | ||||||
| Nasdaq: EOLS | Exited | Pharmaceutical Preparations | COM | 0 | -675,000 | -100.0% | -$4M | $463M | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: BBIO | Exited | Pharmaceutical Preparations | COM | 0 | -170,172 | -100.0% | -$4M | $15.2B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Allovir Inc | Exited | COM | 0 | -408,688 | -100.0% | -$4M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Nasdaq: PEPG | Exited | Pharmaceutical Preparations | COM | 0 | -800,000 | -100.0% | -$4M | $370M | Q4 2025 | 17 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| Proqr Thrapeutics N V | Exited | SHS EURO | 0 | -1,835,991 | -100.0% | -$3M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| Prelude Therapeutics Inc | Nasdaq: PRLD | Exited | Pharmaceutical Preparations | COM | 0 | -947,049 | -100.0% | -$3M | $261M | Q2 2026 | 14 Aug 2026 | Q1 2026 | Q1 2026 | 13F, Q1 2026 | |||
| iBio, Inc. | Nasdaq: IBIO | Exited | Pharmaceutical Preparations | COM NEW | 0 | -1,583,000 | -100.0% | -$3M | $56M | Q2 2026 | 14 Aug 2026 | Q4 2025 | Q1 2026 | 13F, Q1 2026 | |||
| Nasdaq: SLDB | Exited | Biological Products, (No Diagnostic Substances) | COM NEW | 0 | -744,450 | -100.0% | -$3M | $719M | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | ||||
| Design Therapeutics, Inc. | Nasdaq: DSGN | Exited | Pharmaceutical Preparations | COM | 0 | -426,683 | -100.0% | -$3M | $597M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | |||
| Kyverna Therapeutics, Inc. | Nasdaq: KYTX | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -450,000 | -100.0% | -$2M | $276M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | |||
| Generation Bio Co | Exited | COM | 0 | -2,046,867 | -100.0% | -$2M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Whitehawk Therapeutics, Inc. | Nasdaq: WHWK | Exited | Pharmaceutical Preparations | COM | 0 | -1,091,417 | -100.0% | -$2M | $184M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | |||
| Camp4 Therapeutics Corp | Nasdaq: CAMP | Exited | Pharmaceutical Preparations | COM | 0 | -325,000 | -100.0% | -$2M | $251M | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | |||
| MACROGENICS INC | Nasdaq: MGNX | Exited | Pharmaceutical Preparations | COM | 0 | -1,602,717 | -100.0% | -$2M | $127M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | |||
| Keros Therapeutics, Inc. | Nasdaq: KROS | Exited | Pharmaceutical Preparations | COM | 0 | -187,500 | -100.0% | -$2M | $224M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | |||
| Kalaris Therapeutics, Inc. | Nasdaq: KLRS | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -201,718 | -100.0% | -$2M | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | ||||
| Nasdaq: CMPS | Exited | Pharmaceutical Preparations | SPONSORED ADS | 0 | -265,137 | -100.0% | -$2M | $1.2B | Q4 2025 | 17 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| TScan Therapeutics, Inc. | Nasdaq: TCRX | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -662,833 | -100.0% | -$0.9M | $10M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | |||
| Hookipa Pharma Inc | Exited | COM NEW | 0 | -388,861 | -100.0% | -$0.8M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Aligos Therapeutics, Inc. | Nasdaq: ALGS | Exited | Biological Products, (No Diagnostic Substances) | COM NEW | 0 | -88,569 | -100.0% | -$0.7M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Nasdaq: ARTV | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -41,453 | -100.0% | -$0.4M | $189M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Upstream Bio, Inc. | Nasdaq: UPB | Exited | Pharmaceutical Preparations | COM | 0 | -60,000 | -100.0% | -$0.4M | $110M | Q2 2025 | 14 Aug 2025 | Q4 2024 | Q1 2025 | 13F, Q1 2025 | |||
| Nasdaq: MREO | Exited | Pharmaceutical Preparations | SPON ADS | 0 | -1,000,000 | -100.0% | -$0.3M | $44M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q2 2026 | 13F, Q2 2026 | ||||
| Caremax Inc | Exited | *W EXP 06/08/202 | 0 | -100,000 | -100.0% | -$0.2M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| Nasdaq: GLUE | Exited | Biological Products, (No Diagnostic Substances) | COM | -100.0% | -$0.2M | $761M | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Allakos Inc | Exited | COM | 0 | -192,346 | -100.0% | -$0.1M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| Surrozen, Inc./DE | Nasdaq: SRZN | Exited | Biological Products, (No Diagnostic Substances) | *W EXP 08/01/203 | 0 | -4,444 | -100.0% | -$0.1M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 |
Areesha SaifFounder + Portfolio Manager · Present
Basheer ZadaPRINCIPAL · Present
Caroline ChoPRINCIPAL · Present
Caroline StoutPartner · Present
Daniel ChizhikovPartner · Present
Oleg NodelmanFounder + Portfolio Manager · Present
Sarah MarriottPartner, COO + GC · Present
Scott PerlenPartner, COO + GC · Present